Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $207000.0.

  • Harvard Bioscience's Capital Expenditures fell 7647.73% to $207000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 6501.73%. This contributed to the annual value of $2.6 million for FY2024, which is 4787.47% up from last year.
  • Harvard Bioscience's Capital Expenditures amounted to $207000.0 in Q3 2025, which was down 7647.73% from $89000.0 recorded in Q2 2025.
  • Harvard Bioscience's Capital Expenditures' 5-year high stood at $880000.0 during Q3 2024, with a 5-year trough of $89000.0 in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's median Capital Expenditures value was $442000.0 (recorded in 2022), while the average stood at $422421.1.
  • Per our database at Business Quant, Harvard Bioscience's Capital Expenditures surged by 45937.5% in 2021 and then tumbled by 8911.98% in 2025.
  • Harvard Bioscience's Capital Expenditures (Quarter) stood at $358000.0 in 2021, then plummeted by 34.36% to $235000.0 in 2022, then skyrocketed by 253.19% to $830000.0 in 2023, then plummeted by 63.73% to $301000.0 in 2024, then plummeted by 31.23% to $207000.0 in 2025.
  • Its last three reported values are $207000.0 in Q3 2025, $89000.0 for Q2 2025, and $513000.0 during Q1 2025.